港股早评恒指高开0.46%蓝筹股全线上涨中信建投高开3%
格隆汇6月27日丨隔夜美股涨跌不一,标普指数录得四连跌。恒指当月期货夜盘收涨0.61%。昨日恒指收涨0.13%,生物科技板块领涨,中船防务飙升超7%。今日开盘,主要股指高开,恒指涨0.46%,报28352.94点。国指平开。主板盘前成交15.23亿港元。从板块表现看,环保股大涨超6%领涨,燃气股、光伏太阳能、石油股、濠赌股盘前上涨,煤炭股跌超4%表现最差,重型机械、家电股、黄金股小幅下跌。个股方面,恒安国际高开2.14%领涨恒指成份股;碧桂园涨近2%;中信股份、银河娱乐、华润置地涨超1%;舜宇、中国平安、汇丰控股、三桶油等多数蓝筹上涨;中信建投高开3%;保利协鑫涨3.6%为最佳港股通标的股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.